Influence of frosted haptics on rotational stability of toric intraocular lenses
- PMID: 34302005
- PMCID: PMC8302686
- DOI: 10.1038/s41598-021-94293-3
Influence of frosted haptics on rotational stability of toric intraocular lenses
Abstract
We investigated the unfolding property and rotational stability of a new toric intraocular lens (IOL); TECNIS toric II (toric-II, ZCW, Johnson & Johnson) that is an improved version of TECNIS toric IOL (toric-I, ZCV). Both IOLs are based on an identical platform, except for the frosted haptics with toric-II IOL. The study consisted of two parts; experimental study and clinical, retrospective, case series. Experimental study indicated that the overall time from IOL ejection to unfolding to 11 mm was significantly shorter with toricII than toric-I IOLs (p = 0.032), due to the earlier separation of the haptics from the optic with toric-II IOL. Clinical study included 131 eyes of 99 patients who had undergone phacoemulsification and toric IOL implantation. At 3 months postoperatively, toric-II IOL showed significantly better rotational stability than toric-I IOL, including smaller residual manifest astigmatism (p = 0.018), less amount of axis misalignment from the intended axis (p = 0.04), lower incidence of misalignment > 10º (p = 0.0044), and less degree of prediction errors (p = 0.043). Postoperative uncorrected distance visual acuity tended to be better in the toric-II than in the toric-I groups, with marginal statistical difference (p = 0.057). TECNIS toric II IOL with the frosted haptics showed significantly better rotational stability than its predecessor, probably due to quicker unfolding and greater friction with the capsular bag.
© 2021. The Author(s).
Conflict of interest statement
Dr. Tetsuro Oshika received compensation as a consultant from Alcon, Johnson & Johnson Vision, Santen Pharmaceutical, and Mitsubishi Tanabe. He receives research support from Santen Pharmaceutical, Tomey, Alcon, Senju Pharmaceutical, Johnson & Johnson Vision, HOYA, KOWA Pharmaceutical, Otsuka Pharmaceutical, Novartis, Pfizer, and Topcon. Other authors do not have any conflict of interest.
Figures






References
MeSH terms
LinkOut - more resources
Full Text Sources